Coya Therapeutics, Inc. (COYA) stock
COYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/3017% above fair value
$3.09+0.07 (+2.32%)
Close on Nov 18, 2026Market cap $72.48MP/E –Yield –
Coya Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Coya Therapeutics's revenue for the twelve months ending Sep 30, 2026 was $4.69M, up 17.6% year over year. For fiscal 2025 it was $7.95M, up 123.6% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.95M | +123.6% |
| FY2024 | Dec 31, 2024 | $3.55M | -40.8% |
| FY2023 | Dec 31, 2023 | $6.00M | – |
| FY2022 | Dec 31, 2022 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $234.13K | -93.4% |
| Q2 FY2026 | Jun 30, 2026 | $243.75K | +49.0% |
| Q1 FY2026 | Mar 31, 2026 | $251.15K | -2.6% |
| Q4 FY2025 | Dec 31, 2025 | $3.96M | +202768.8% |
| Q3 FY2025 | Sep 30, 2025 | $3.56M | – |
| Q2 FY2025 | Jun 30, 2025 | $163.62K | -95.2% |
| Q1 FY2025 | Mar 31, 2025 | $257.88K | +103.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.95K | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $0 | – |
| Q2 FY2024 | Jun 30, 2024 | $3.43M | – |
| Q1 FY2024 | Mar 31, 2024 | $126.84K | – |
| Q4 FY2023 | Dec 31, 2023 | $6.00M | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
| Q1 FY2023 | Mar 31, 2023 | $0 | – |
See a number that looks wrong?